ODAC Unanimously Recommends GSK’s Promacta For ITP
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA, committee members struggle to find ways to discourage long-term use of the drug for the chronic condition.
You may also be interested in...
GSK’s Promacta And Amgen’s Nplate Face Off In ITP Market
GlaxoSmithKline/Ligand's Promacta (eltrombopag) received FDA approval Nov. 20 as a second-line treatment of thrombocytopenia in patients with the rare blood disorder chronic idiopathic thrombocytopenic purpura. The approval was widely anticipated, although it came five months after the drug's original PDUFA date
GSK’s Promacta And Amgen’s Nplate Face Off In ITP Market
GlaxoSmithKline/Ligand's Promacta (eltrombopag) received FDA approval Nov. 20 as a second-line treatment of thrombocytopenia in patients with the rare blood disorder chronic idiopathic thrombocytopenic purpura. The approval was widely anticipated, although it came five months after the drug's original PDUFA date
GSK’s Promacta And Amgen’s Nplate To Face Off In ITP Market
GlaxoSmithKline’s thrombocytopenia treatment for patients with idiopathic thrombocytopenic purpura will launch the week of Nov. 24.